Hormonal Contraception Use and Cabotegravir Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077

Ítems similars

• Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus–uninfected Individuals in HPTN 077
  per: Landovitz, Raphael J, et al.
  Publicat: (2020)
• Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077
  per: Tolley, Elizabeth E., et al.
  Publicat: (2020)
• Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial
  per: Landovitz, Raphael J., et al.
  Publicat: (2020)
• Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial
  per: Landovitz, Raphael J., et al.
  Publicat: (2018)
• Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study
  per: Seneviratne, Herana Kamal, et al.
  Publicat: (2021)